8-K

================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

                Date of Report (Date of earliest event reported):
                                 January 1, 2008


                               TRANSGENOMIC, INC.
             ------------------------------------------------------
             (Exact name of registrant as specified in its charter)


       Delaware                      000-30975                   911789357
- ------------------------      ----------------------      ----------------------
(State of Incorporation)     (Commission File Number)         (IRS Employer
                                                          Identification Number)


  12325 Emmet Street, Omaha, Nebraska                              68164
 --------------------------------------                   ----------------------
(Address of principal executive offices)                        (Zip Code)


                                 (402) 452-5400
              ----------------------------------------------------
              (Registrant's telephone number, including area code)


                                 Not applicable
      ---------------------------------------------------------------------
          (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

|_|   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))

================================================================================


Item 5.02 Election of Director.

      On January 1, 2008, the Registrant's Board of Directors appointed David P.
Pauluzzi to serve as a Class III Director. Mr. Pauluzzi has not been appointed
to any committees of the Board of Directors at this time. There are no family
relationships between Mr. Pauluzzi and any other director or executive officer
of the Registrant and he was not selected by the Board of Directors to serve as
a Director pursuant to any arrangement or understanding with any person. Mr.
Pauluzzi has not engaged in any transaction with the Registrant that would be
reportable as a related party transaction under the rules of the SEC.


Item 9.01 Financial Statements and Exhibits.

      99.1 Press Release, dated February 5, 2008, announcing the appointment of
David P. Pauluzzi to the Registrant's Board of Directors.


                                   SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.


Dated:  February 5, 2008                 TRANSGENOMIC, INC.


                                         By: /s/ Debra A. Schneider
                                             -----------------------------------
                                             Debra A. Schneider
                                             Chief Financial Officer

EX-99.1

           Transgenomic Appoints David Pauluzzi to Board of Directors
 Former Quest Executive Director Brings Extensive Strategic Marketing Expertise


OMAHA, Neb., February 5, 2008 - Transgenomic, Inc. (OTCBB: TBIO.OB), today
announced that it has appointed David P. Pauluzzi to its Board of Directors. Mr.
Pauluzzi is currently a consultant at Water Street Healthcare Partners, a
Chicago-based private equity firm specializing in the healthcare sector.

Prior to his current position, Mr. Pauluzzi served as Executive Director/VP of
Quest Diagnostics, the nation's leading provider of diagnostic testing,
information and services, where he directed operations, marketing and sales for
its Esoteric Anatomic Pathology Business and built a direct sales and marketing
organization for its Hospital Division. He also served as V.P. of Sales and
Marketing and Chief Operating Officer for US LABS, a national anatomic pathology
reference laboratory, where he hired and developed the Company's sales and
marketing organization and launched national marketing and re-branding
initiatives. Mr. Pauluzzi has also served as Senior Director of World Wide
Marketing for Ventana Medical Systems, a global leader in tissue-based cancer
diagnostics, and as District Sales Manager and International Marketing Manager
for the Diagnostics Division of global healthcare company Abbott Laboratories.

Craig Tuttle, Transgenomic President and Chief Executive Officer, stated, "Mr.
Pauluzzi brings more than 20 years of worldwide diagnostic and clinical
laboratory experience with both leading and emerging healthcare service
companies that includes extensive expertise in strategic marketing, developing
and managing sales organizations, and senior level diagnostic product and
systems sales. His cancer diagnostic and services industry experience includes
anatomic pathology, genomics, proteomics and the pharmacogenomics market serving
physicians, labs and hospitals. We are excited to have him join the Company's
Board of Directors."

About Transgenomic:
Transgenomic is a global biotechnology company that provides unique products and
services for automated high sensitivity genetic variation and mutation analysis.
Their offerings include systems, products, discovery and laboratory testing
services to the academic and medical research, clinical laboratory and
pharmaceutical markets in the fields of pharmacogenomics and personalized
medicine. Specific offerings include WAVE(R) DHPLC Systems, related consumables
and assay kits, cytogenetics automated systems, Transgenomic Molecular Clinical
Reference Laboratory and Pharmacogenomics Research Services. Transgenomic's two
laboratory services divisions utilize these technologies and expertise to
provide a menu of mutation scanning tests for over 700 cancer-associated genes
and more than 60 validated diagnostic tests to meet the needs of pharmaceutical
and biotech companies, research and clinical laboratories, physicians and
patients. For more information about the innovative systems, products and
services offered by Transgenomic, please visit: www.transgenomic.com.



Transgenomic Cautionary Statements
Certain statements in this press release constitute "forward-looking statements"
of Transgenomic within the meaning of the Private Securities Litigation Reform
Act of 1995, which involve known and unknown risks, uncertainties and other
factors that may cause our actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. Forward-looking statements include, but are not limited to, those
with respect to management's current views and estimates of future economic
circumstances, industry conditions, company performance and financial results,
including the ability of the Company to grow its involvement in the diagnostic
products and services markets. The known risks, uncertainties and other factors
affecting these forward-looking statements are described from time to time in
Transgenomic's reports to the Securities and Exchange Commission. Any change in
such factors, risks and uncertainties may cause the actual results, events and
performance to differ materially from those referred to in such statements.
Accordingly, the company claims the protection of the safe harbor for
forward-looking statements contained in the Private Securities Litigation Reform
Act of 1995 with respect to all statements contained in this press release. All
information in this press release is as of the date of the release and
Transgenomic does not undertake any duty to update this information, including
any forward-looking statements, unless required by law.

For confirmation of release or further information, please contact:

   Debra Schneider                              Todd Kehrli or Jim Byers
   Chief Financial Officer                      Investor Relations
   Transgenomic, Inc.                           MKR Group, Inc.
   12325 Emmet Street
   Omaha, NE 68164

   Phone: 402.452.5400                          Phone:  323.468.2300
   Fax: 402.452.5461

   investorrelations@transgenomic.com           tbio@mkr-group.com